News

NEW website launched presenting our Bioanalytical Services

March 14, 2016 - Company News
We are happy to announce the launch of a new dedicated website presenting our expertise and offerings within bioanalytical services. Wieslab Bioanalytical Services - your dedicated bioanalytical partner with a knowledge base that can make a difference to your study.

MALMÖ, Sweden, 14 March, 2016 — Euro Diagnostica AB (Euro Diagnostica) is expanding and as part of our growing business we now offer dedicated bioanalytical services for clients within pharma, biotech and CRO.

For the last 20+ years Wieslab, and parent company Euro Diagnostica, have been developing and manufacturing immunoassays of high quality delivering fast test results. The merge with Biomonitor in 2014 strengthened our service platform with a GLP laboratory with a 10 year track record of providing bioanalytical support in non-clinical and clinical phase I-III studies.

We are now happy to announce the launch of a new dedicated website presenting our expertise and offerings within bioanalytical services.

At Wieslab Bioanalytical Services we combine deep knowledge from clinical diagnostic testing within immune-mediated diseases with the ability to provide GLP compliant laboratory support in the drug development process. Our Sweden-based GLP compliant laboratory combines novel technologies with deep scientific expertise in immunological interactions to develop, optimize and validate a wide range of assays for sensitive and specific quantitation of biological drugs.

The expert resources, our highly experienced scientists and QA professionals, and the extensive platforms available in our in-house laboratory ensure high quality science, data integrity, and regulatory compliance through all phases of our services. Our bioanalytical services are focused on large molecules (biologics and biosimilars) within immune-mediated diseases and non-clinical as well as phase I - III clinical studies.

We focus on where we can make a difference in your drug development project. Our capabilities include:

  • Biomarker studies
  • Immunogenicity studies: ADA – screening and confirmatory assays (ELISA, RIA and cell based)
  • Bioanalysis – Pharmacokinetic (PK) studies
  • CMC support for lot release of drugs
  • Consultant services to optimize your study and submission success

Click here to visit the Bioanalytical Services website

Call us to discover what value we can add to your project!

Contact:

Michael Akoh, Wieslab Vice President

P: +46 (40) 53 76 31

E: michael.akoh@wieslab.com

 

« Back